Seeking Alpha

Belgian drug developer Galapagos signs a deal worth up to $1.35B with Abbott Laboratories (ABT)...

Belgian drug developer Galapagos signs a deal worth up to $1.35B with Abbott Laboratories (ABT) for the development and production of an oral drug to treat arthritis and other auto-immune diseases. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|